Biotech · Private company
CellCentric Ltd.
Track this companyFree. Adds CellCentric Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials43 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- InoPdPhase 3 · Multiple Myeloma RefractoryClinicalTrials.gov · fetched Nov 12, 2026
- Investigator's choice of SATPhase 3 · Multiple Myeloma RefractoryClinicalTrials.gov · fetched Nov 12, 2026
- Abiraterone acetatePhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 2 · Haematological MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- BortezomibPhase 2 · Haematological MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- CCS1477Phase 2 · Haematological MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- CCS1477Phase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- DarolutamidePhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 2 · Multiple Myeloma RefractoryClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 2 · Haematological MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- EnzalutamidePhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- InobrodibPhase 2 · Multiple Myeloma RefractoryClinicalTrials.gov · fetched Nov 12, 2026
- OlaparibPhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- PomalidomidePhase 2 · Haematological MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- PomalidomidePhase 2 · Multiple Myeloma RefractoryClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 2 · Haematological MalignancyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple MyelomaPHASE3 · RECRUITING · started Aug 1, 2026ClinicalTrials.gov NCT07772024 · fetched Nov 12, 2026
- Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaPHASE2 · RECRUITING · started Jan 22, 2026ClinicalTrials.gov NCT07096778 · fetched Nov 12, 2026
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesPHASE1_PHASE2 · RECRUITING · started Aug 9, 2019ClinicalTrials.gov NCT04068597 · fetched Nov 12, 2026
- Study to Evaluate CCS1477 in Advanced TumoursPHASE1_PHASE2 · COMPLETED · started Jul 23, 2018ClinicalTrials.gov NCT03568656 · fetched Nov 12, 2026